What is the clinical evidence from this study?

Population: Hypertension (n=15). Intervention: Captopril vs. Baseline (precaptopril). Primary outcome: Blood pressure and plasma norepinephrine concentration (p=<0.05).

What question did this study set out to answer?

The research aims to explore how captopril affects plasma norepinephrine levels and blood pressure in hypertensive patients.

January 1, 1983Clinical and Experimental Hypertension Part A Theory and Practice

Further Studies on the Hypernoradrenergic State of Treated Hypertensives: Effect of Captopril

Q: What are the key findings of this study?

Captopril significantly lowered blood pressure and plasma norepinephrine concentrations in both hypernoradrenergic and eunoradrenergic hypertensive patients (p<0.05).

Q: What question did this study set out to answer?

The research aims to explore how captopril affects plasma norepinephrine levels and blood pressure in hypertensive patients.

View Full Paper

Ask AI

Bookmark

Key result

Captopril significantly lowered blood pressure and plasma norepinephrine concentrations in both hypernoradrenergic and eunoradrenergic hypertensive patients (p<0.05).

Why the study?

Does captopril reduce blood pressure and plasma norepinephrine in hypernoradrenergic and eunoradrenergic hypertensive patients?

Key Points

The research aims to explore how captopril affects plasma norepinephrine levels and blood pressure in hypertensive patients.
Investigated two groups: five severely hypertensive patients and ten untreated mildly hypertensive patients.
Administered captopril at doses of 12.5mg and 100-150mg, measuring plasma norepinephrine concentration and blood pressure changes.
Utilized correlations between blood pressure response and plasma norepinephrine levels.
In severely hypertensive patients, captopril reduced blood pressure from 180/102 mmHg to 132/77 mmHg (p<0.05).
Chronic administration did not further reduce blood pressure and plasma norepinephrine decreased significantly post-treatment to 752 pg/ml (p<0.05).
Mild hypertensive patients saw blood pressure change from 146/98 mmHg to 137/91 mmHg after a 25-100mg dose (diastolic p<0.05).

Structured PICO

Does captopril reduce blood pressure and plasma norepinephrine in hypernoradrenergic and eunoradrenergic hypertensive patients?

Population

15 hypertensive patients (5 severe hypernoradrenergic on triple therapy and 10 untreated mild) treated with captopril and followed for up to 3 months.

Intervention

Captopril (acute dose of 12.5 mg or 25-100 mg, followed by chronic administration of 100-150 mg tid or bid for 2-3 months)

Outcome

Blood pressure and plasma norepinephrine concentration at 2 hours and 2-3 monthssurrogate

Main Result

p-value: p=<0.05

Captopril effectively lowers blood pressure in hypertensive patients without causing reflex sympathetic activation, and may even dampen sympathetic nervous system activity.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Captopril may lower norepinephrine without reflex activation in hypertension; leaves open outcome benefits across subtypes.

Cite This Study

Mitchell et al. (1983) studied Hypertension (n=15). Captopril vs. Baseline (precaptopril) was evaluated on Blood pressure and plasma norepinephrine concentration (p=<0.05). Captopril significantly lowered blood pressure and plasma norepinephrine concentrations in both hypernoradrenergic and eunoradrenergic hypertensive patients (p<0.05).

synapsesocial.com/papers/6a2390659e1c90a91c08e6f4 https://doi.org/10.3109/10641968309051798

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Further Studies on the Hypernoradrenergic State of Treated Hypertensives: Effect of Captopril

Key Points

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Topics

Further Studies on the Hypernoradrenergic State of Treated Hypertensives: Effect of Captopril

Key Points

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider